Making a morphologic distinction between hypocellular refractory anemia (hypo RA) and aplastic anemia (AA) is difficult. To investigate the significance of hemoglobin F-containing erythroblasts (F-blasts) and p53 expression in making the distinction between hypo RA and acquired AA, we immunohistochemically assessed F-blasts and p53 in bone marrow specimens from 16 patients with hypo RA, 31 patients with acquired AA, and 15 hematologically normal individuals. F-blast production was elevated in 87.5% (14/16) of patients with hypo RA, but in only 3.2% (1/31) of patients with AA (P < .01). p53 was over-expressed in 75.0% (12/16) of hypo RA patients and in 6.4% (2/31) of AA patients (P < .01). The mean contents of F-blasts and p53-positive cells in patients with hypo RA were 6.31% ± 3.27% and 7.54% ± 4.36%, respectively, of all bone marrow cells, which were significantly higher than for patients with AA (0.35% ± 0.46% and 0.58% ± 1.29%, P < .01). In conclusion, a high prevalence of elevated F-blast production is noted in hypo RA, suggesting that the assessment of F-blasts in bone marrow can be used as an additional tool for differentiating hypo RA from acquired AA.
Elghetany MT, Vyas S, Yuoh G. Significance of p53 overexpression in bone marrow biopsies from patients with bone marrow failure: aplastic anemia, hypocellular refractory anemia, and hypercellular refractory anemia.Ann Hematol. 1998;77:261–264.CrossRefPubMedPubMedCentralGoogle Scholar
Elghetany MT. p53 overexpression in bone marrow biopsies in refractory anemia and aplastic anemia: impact of antibody selection.Leuk Res. 2000;24:975–977.CrossRefPubMedGoogle Scholar
Choi JW, Kim Y, Fujino M, Ito M. A new anti-hemoglobin F antibody against synthetic peptide for the detection of F-cell precursors (F-blasts) in bone marrow.Int J Hematol. 2001;74:277–280.CrossRefPubMedGoogle Scholar
Elghetany MT, Hudnall SD, Gardner FH. Peripheral blood picture in primary hypocellular refractory anemia and idiopathic acquired aplastic anemia: an additional tool for differential diagnosis.Haematologica. 1997;82:21–24.PubMedGoogle Scholar
Kurotaki H, Tsushima Y, Nagai K, Yagihashi S. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.Acta Haematol. 1999;102:115–123.CrossRefGoogle Scholar
Kikukawa M, Aoki N, Sakamoto Y, Mori M. Study of p53 in elderly patients with myelodysplastic syndromes by immunohistochem-istry and DNA analysis.Am J Pathol. 1999;155:717–721.CrossRefPubMedPubMedCentralGoogle Scholar